Skip to main content

Table 1 Baseline patient characteristics by vaccination status

From: The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study

  Vaccination status
Baseline characteristics, n(%) Vaccinated
n= 551
Unvaccinated
n= 43,564
Age groups (years)   
   50 to 59 202 (36.7) 30,156 (69.2)
   60 to 64 275 (49.9) 9,573 (22.0)
   65 and older 74 (13.4) 3,835 (8.8)
Women 352 (63.9) 27,091 (62.2)
Inflammatory/Autoimmune disease   
   RA 206 (37.4) 19,120 (43.9)
   Psoriatic arthritis 11 (2.0) 856 (2.0)
   Psoriasis 146 (26.5) 10,566 (24.3)
   Inflammatory bowel diseases 136 (24.7) 8,503 (19.5)
   Ankylosing spondylitis 8 (1.5) 625 (1.4)
   Multiple diseases 44 (8.0) 3,894 (8.9)
Medicationsa   
   TNF antagonists user 27 (4.9) 4,186 (9.6)
   Other biologics user 0 (0) 198 (0.5)
   Conventional DMARDs user 92 (16.7) 9,312 (21.4)
   Oral glucocorticoidsb   
None 456 (82.8) 34,267 (78.7)
Low 86 (15.6) 8,041 (18.5)
Medium 7 (1.3) 902 (2.1)
High 2 (0.4) 354 (0.8)
Charlson comorbidity index   
   0 287 (52.1) 19,971 (45.8)
   1 181 (32.9) 16,565 (38.0)
   ≥ 2 83 (15.1) 7,028 (16.1)
Inpatient hospitalization   
   No 466 (84.6) 36,158 (83.0)
   Yes 45 (15.4) 7,406 (17.0)
Number of outpatient physician visits   
   0-2 83 (15.1) 8,705 (20.0)
   3-5 227 (41.2) 16,843 (38.7)
   6-10 185 (33.6) 13,376 (30.7)
   11 and more 54 (9.8) 4,642 (10.7)
  1. DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor. aMeasured in the 6-month baseline period before the start of observation
  2. bCumulative average daily prednisone-equivalent glucocorticoid dose in the past 183 days: none, low (< 10 mg/day), medium (10-20 mg/day), and high (> 20 mg/day).